期刊文献+

肾癌的非手术治疗现状 被引量:6

下载PDF
导出
摘要 肾癌(renal cell carcinoma,RCC)是泌尿系统最常见的恶性肿瘤之一,其发病率占全身恶性肿瘤的3%,居泌尿系统肿瘤的第二位。国际抗癌协会报道RCC每10年发病率上升2%,每年全球新增RCC病例约190 000例,每年死于RCC的病例超过91 000例。我国RCC每年以2.5%的速度递增,约有20%-30%的肾癌患者就诊时已出现不同程度的扩散或转移,有20%-40%的术后患者仍会出现远处转移。
作者 郭海滨
出处 《西南军医》 2011年第4期710-712,共3页 Journal of Military Surgeon in Southwest China
  • 相关文献

参考文献18

  • 1Muss HB, Costanzi JJ. Leavitt R. et al. Recombinant alia interferon in renal cell careinoma:a randomized trial of two routes of administration [J]. J Clin 0nco1,1987,5:286 -291.
  • 2Atkins MB, Regan M , McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma [J]. Clin Cancer Res,2004,171:1071 - 1076.
  • 3Huland E, Heinzer H, Huland H. Treatment of pulmonary metastatic renal -cell carcinoma in 116 patients using inhaled intedeukin- 2 ( IL -2) [ J]. Antieaneer aes. 1999.19:2679 -2683.
  • 4McDermott D, Flaherty L. A randomized phaseⅢ trial of high - dose interleukin - 2 (HD IL2) versus subcutaneous ( SC ) IL2/interferon (IFN) in patients with metastatic renal cell carcinoma(RCC). A Cy- tokine Working Group Study [J]. Proc Am Soc Clin Oncol,2001,20: 172a.
  • 5Amato RJ. Chemotherapy for renal cell carcinoma [ J]. Semin Oneol. 2000.27 : 177 - 186.
  • 6Fizazi K,Rolland F, Chevreau C, et al. A phase Ⅱ study of irinote- can in patients with advanced renal eell carcinoma [J]. Cancer. 2003,98:61 -65.
  • 7Rini BI. Vogelzang NJ. Dumas MC,et al. Phase Ⅱ trial of weekly in- travenous gemeitabine with continuous infusion fluorouraeil in patients with metastatic renal cell cancer [J]. J Clin Oneol,2000, 18:2419 - 2426.
  • 8Wilhelm SM, Carter C, Tang L, et al. BAY43 -9006 exhibits broad spectrum oral an titumor activity and targets the RAF/MEK/ERKpathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [ J]. Cancer Res ,2004,64 (19) :7099 - 7109.
  • 9Bleumer I,Knuth A. Oosterwijk E. et al. A phase Ⅱ trial of chimeric m0noclonal antibody G 250 for advanced rena/cell carcinoma patients [J]. Br J Cancer,2004,90:985 -990.
  • 10Bleumer l,Oosterwijk E,Oosterwijk. Wakka JC. et al. A clinical trial with chimeric monoclonal antibody WX - G3250 and low dose intrleu- kin- 2 pulalng scheme for advanced renal cell carcinoma [J]. J Urol. 2006.175 ( 1 ) :57 -62,.

同被引文献42

  • 1王欢,周芳坚,王其京,秦自科,黄丽惜,刘卓炜,韩辉,李永强,陈诗萍,夏建川.负载自体肿瘤细胞裂解物的DC疫苗联合CIK治疗晚期肾癌的临床观察——附10例报告[J].癌症,2006,25(5):625-630. 被引量:51
  • 2吴登龙 宋建达 吴直江.肾癌患者细胞免疫功能变化的观察.上海医学,1996,:211-213.
  • 3Mekhail TM, Abou-Jawde RM, Bou Merhi G, et al. Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma [J]. J Clin Oncol, 2005, 23(4) : 832-841.
  • 4Garcia JA, Rini BI. Recent progress in the management of ad- vanced renal cell arcinoma [ J ]. CA Cancer J Clin, 2007, 57 (2) : 112-125.
  • 5Uchida K, Miyao N, Masumori N, et al. Recurrence of renal cell carcinoma more than 5 years after nephrectomy [ J ]. Int J Urol, 2002, 9(1) : 19-23.
  • 6Algaba F. Rereading the renal cell tumors [ J]. Int J Surg Pathol, 2010, 18(3Suppl) : 94S-97S.
  • 7Su X, Zhang L, Jin L, et al. Immunotherapy with cytokine-in- duced killer ceils in metastatic renal cell carcinoma [ J ]. Cancer Biother Radiopharm, 2010, 25 ( 4 ) : 465-470.
  • 8冯磊.树突状细胞免疫治疗肾癌临床分析[D].山东大学硕士学位论文.2010:5-30.
  • 9Laschos KA, Papazisis KT, Kontovinis LF, et al. Targeted treat- ment for metastatic renal cell carcinoma and immune regulation [J]. J BUON, 2010, 15(2) : 235-240.
  • 10Somasundaram R, Jacob L, Swoboda R, et al. Inhibition of cyto- lytic T lymphocyte proliferation by autologous CIM ~/CD25 ~ regu- latory T cells in a colorectal carcinoma patient is mediated by trans- forming growth factor-~ [J]. Cancer Res, 2002, 62( 11 ) : 5267- 5272.

引证文献6

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部